(Q36194583)

12 August 2017

1 reference

title

Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment (English)

1 reference

12 August 2017

1 reference

1 reference

Alessandro Corso

1

1 reference

12 August 2017

Eleonora Ferretti

series ordinal

2

1 reference

12 August 2017

Mario Lazzarino

series ordinal

3

1 reference

12 August 2017

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

215-224

1 reference

Targeted therapy for multiple myeloma

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Bisphosphonates: preclinical aspects and use in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Structure-activity relationships of various bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Bisphosphonates in the treatment of malignant bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500094714

10.1080/10245330500094714

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference